Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. (NASDAQ: AMIX) is a development-stage medical device company focused on precision nerve-targeted treatments for diseases involving the nervous system. News about Autonomix often centers on clinical data from its proof-of-concept studies, intellectual property milestones, and updates on its catheter-based nerve-sensing and ablation platform.
Recent announcements have highlighted subgroup analyses from the company’s PoC 1 study in pancreatic cancer pain, presented at major scientific meetings such as the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. These updates describe rapid and durable pain relief, reductions in opioid use, and quality-of-life improvements in patients with severe pancreatic cancer-related pain, including those with advanced and metastatic disease. Autonomix has also reported on its follow-on PoC 2 phase, which evaluates additional visceral cancers that signal pain through the celiac plexus and earlier-stage pancreatic cancers.
Another key theme in AMIX news is intellectual property. The company has announced U.S. and European patents titled “Controlled and Precise Treatment of Cardiac Tissues,” covering systems and methods that sense autonomic or cardiac signals, map neural targets, and deliver feedback-guided neuromodulation, denervation, and ablation. These patents support Autonomix’s stated strategy to build a global IP portfolio in nerve sensing and modulation with potential applications across cardiology, hypertension, interventional pain management, pulmonary and gastrointestinal disorders, and other high-burden diseases.
Investors following AMIX news can also expect updates on capital markets activity, including private placements, purchase agreements with institutional investors, and at-the-market sales agreements disclosed in SEC filings. For a consolidated view of Autonomix-related headlines, clinical presentations, patent issuances, and financing developments, this news feed provides an organized way to track how the company’s nerve-sensing and ablation platform is progressing through clinical and corporate milestones.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released its latest CEO Corner segment featuring CEO Brad Hauser. The segment discusses two key updates: the company's recent longer-term post hoc analysis from its first-in-human proof-of-concept study (PoC 1) and progress towards U.S. clinical trials scheduled to begin in 2026.
Autonomix Medical (NASDAQ: AMIX) has initiated a crucial Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System, targeting pancreatic cancer pain treatment. The study, conducted at CBSET research institute, represents a significant step toward FDA regulatory approvals.
The company remains on track to submit its Investigational Device Exemption (IDE) and, pending approval, begin U.S. clinical trials in 2026 to support a De Novo FDA application. CEO Brad Hauser highlighted this as a critical milestone in their regulatory pathway.
Autonomix's first-in-class technology platform shows potential applications across multiple therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and pulmonary and gastrointestinal disorders.
Autonomix Medical (NASDAQ: AMIX) announced that its technology and findings from the first phase of its first-in-human proof-of-concept study will be presented at the 2025 CIRSE Annual Congress in Barcelona, Spain. The presentation, scheduled for September 15, 2025, will focus on pain mitigation in pancreatic adenocarcinoma using neurolysis via transvascular RF ablation.
The presentation will be part of SPHAIRE, CIRSE's interactive area dedicated to artificial intelligence in interventional radiology. Marco Bedoya, VP of Research and Development at Autonomix, will deliver the presentation during the "AI in IR: Machine Learning, SOP and Collaborative Development" session.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment, has released a Virtual Investor "What This Means" segment. In this presentation, Chief Medical Officer Dr. Robert Schwartz discusses the company's recent post hoc analysis of their proof-of-concept human clinical trial (PoC 1).
The analysis revealed significant outcomes including sustained pain reduction, improved quality of life, and 100% zero opioid use among trial participants. The company's focus remains on advancing innovative technologies in neurological disease management.
Autonomix Medical (NASDAQ: AMIX) has reported promising longer-term post hoc analysis results from its PoC 1 study evaluating nerve ablation technology for pancreatic cancer pain treatment. The study demonstrated significant pain reduction of 65.6% (mean 5.08 reduction on VAS pain scale) in responding patients.
Key highlights include 100% opioid-free status among responders at 3-month follow-up, and substantial improvements in quality of life metrics: 76.5% improvement in global health, 51.5% improvement in functional ability, and 50.4% improvement in symptom management. Following these positive results, Autonomix has initiated PoC 2 phase to expand into additional visceral cancers, potentially doubling their addressable market.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO Brad Hauser will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. Management will also conduct one-on-one meetings with qualified investors. The presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website.
Autonomix Medical (NASDAQ: AMIX) has been granted European Patent No. 3,697,298 for its medical device technology focused on capturing and processing physiological signals. The patent strengthens the company's intellectual property portfolio, which now includes 80 issued patents and 40 pending applications.
The patented technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with enhanced sensitivity. The system includes distributed signal acquisition modules for neural mapping procedures, with capabilities spanning coronary artery/vagal nerve mapping, renal mapping, and various other applications in robotic prosthetics and neurotherapy.
Autonomix Medical (NASDAQ:AMIX), a medical device company specializing in precision nerve-targeted treatments, has announced its participation in an upcoming virtual investor webinar. The event will be hosted by Ladenburg Thalmann on Thursday, August 21, 2025, at 1:00 PM ET.
The webinar will feature Brad Hauser, President and CEO of Autonomix, in a discussion moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research at Ladenburg Thalmann. The event will include a Q&A session, with participants able to pre-submit questions via email.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, will participate in the upcoming Webull Financial Corporate Connect Webinar Series focused on Biotech/MedTech companies.
The virtual presentation will be delivered by Brad Hauser, President and CEO, on Thursday, August 21, 2025, at 2:20 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.
Autonomix Medical (NASDAQ: AMIX) has completed the final design review of its groundbreaking intravascular nerve sensing catheter, marking a significant milestone toward U.S. clinical trials. The device, featuring a proprietary microchip-based sensing antenna array, is the first of its kind capable of detecting and differentiating nerve signals in real-time from within blood vessels.
The technology enables a novel "sense, treat and verify" approach, allowing physicians to detect nerve activity, guide energy delivery precisely, and confirm treatment efficacy during procedures. The company is preparing to submit an Investigational Device Exemption (IDE) to commence clinical trials, initially focusing on treating pancreatic cancer pain, with potential applications across multiple therapeutic areas including cardiology, pain management, and pulmonary disorders.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
